Author

Fabiana Mariscotti

Observed names: F. Mariscotti, Mariscotti, Fabiana

Institutions: University of Cambridge, Cambridge Clinical Trials Unit

Observed institutions: The University of Melbourne, University of Cambridge, North East London NHS Foundation Trust, Cambridge Clinical Trials Unit

OpenAlex ID: A5114551400

Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study

2025 · Joanna A. Krupka, Ilias Moutsopoulos, et al. · Journal of Clinical Oncology · 16

Mindfulness‐Based Programmes for Work Performance: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

2025 · Maris Vainre, Tim Dalgleish, et al. · Stress and Health · 7

The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell Lymphoma

2025 · Joanna A Krupka, Ilias Moutsopoulos, et al. · medRxiv · 3

Mindfulness training for work performance: A systematic review and meta-analysis of randomised controlled trials

2022 · Maris Vainre, Tim Dalgleish, et al. · PsyArXiv (OSF Preprints) · 2

Mindfulness training for work performance: A systematic review and meta-analysis of randomised controlled trials

2022 · Maris Vainre, Tim Dalgleish, et al. · PsyArXiv (OSF Preprints) · 1

40 | THE DIRECT STUDY: A ROADMAP FOR ctDNA‐BASED RISK PREDICTION, MOLECULAR PROFILING AND MRD DETECTION IN DIFFUSE LARGE B CELL LYMPHOMA

2025 · J. A. Krupka, I. Moutsopoulos, et al. · Hematological Oncology

Works count: 12

Citation count: 29

H-index: 3

I10-index: 1